### Highlights of This Issue 1973

#### SPECIAL FEATURES

**CCR 20th Anniversary Commentary**

- **1975** CCR 20th Anniversary Commentary: Setting the Stage for Nanoparticle Albumin-Bound Paclitaxel—How Far Science Has Come
  
  Sami I. Bashour and Nuhad K. Ibrahim

**CCR Translations**

- **1978** PLEKHA5: A Key to Unlock the Blood–Brain Barrier?
  
  Sylvia C. Eisele, Corey M. Gill, Ganesh M. Shankar, and Priscilla K. Brastianos

**See related article, p. 2138**

- **1981** The Yin and Yang of Alloreactivity: Chronic Graft-versus-Host Disease and Leukemia Relapse
  
  Saar Gill

**See related article, p. 2020**

**CCR New Strategies**

- **1984** New Strategies in Glioblastoma: Exploiting the New Biology
  
  Howard A. Fine

**Molecular Pathways**

- **1989** Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer
  
  Lynnette Fernandez-Cuesta and Roman K. Thomas

- **1995** Molecular Pathways: A Novel Approach to Targeting Hypoxia and Improving Radiotherapy Efficacy via Reduction in Oxygen Demand
  
  Alexander Lin and Amit Maity

**Reviews**

- **2001** Is This the Time to Introduce Minimal Residual Disease in Multiple Myeloma Clinical Practice?
  
  Bruno Paiva, Noemi Puig, Ramón García-Sanz, and Jesús F. San Miguel on behalf of the Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups

- **2009** Genomic Landscape of Human Papillomavirus–Associated Cancers
  
  Maria Rusan, Yvonne Y. Li, and Peter S. Hammerman

### CANCER THERAPY: CLINICAL

- **2020** Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia
  

**See related commentary, p. 1981**

### PERSONALIZED MEDICINE AND IMAGING

- **2029** Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
  
  Lorraine A. Chantrill, Adnan M. Nagrial, Clare Watson, Amber L. Johns, Mona Martyn-Smith, Skye Simpson, Scott Mead, Marc D. Jones, Jasminder S. Samra, Anthony J. Gill, Nicole Watson, Venessa T. Chiu, Jeremy L. Humphris, Angela Chou, Belinda Brown, Adrienne Money, Marina Pajic, Sean M. Grimmond, David K. Chang, David Thomas, Lucille Sebastian, Katrin Sjoquist, Sony Yip, Nick Pavlakis, Ray Asghari, Sandra Harvey, Peter Grimison, John Simes, and Andrew V. Blankin on behalf of the Australian Pancreatic Cancer Genome Initiative (APGI) and the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial Management Committee of the Australasian Gastrointestinal Trials Group (AGITG)

- **2038** Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy
  
  Ursula Amstutz, Steven M. Offer, Johanna Sistonen, Markus Joerger, Robert B. Diasio, and Carlo R. Largia

- **2045** Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
  
  Brian Parkin, Peter Ouilllette, Mehmet Yildiz, Kamli Saiya-Cork, Kerby Shedden, and Sami N. Malek

---

Downloaded from clincancerres.aacrjournals.org on April 20, 2017. © 2015 American Association for Cancer Research.
CANCER THERAPY: PRECLINICAL

2057 MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

2065 PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance

2075 CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting Cells
Heiko Bruns, Catherine Bessell, Juan Carlos Varela, Carl Haupt, Jerry Fang, Shirin Pasemann, Andreas Mackensen, Mathias Oelke, Jonathan P. Schneck, and Christian Schütz

2084 Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

2096 Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma

BIOLOGY OF HUMAN TUMORS

2107 Chemotherapy Rescues Hypoxic Tumor Cells and Induces Their Reoxygenation and Repopulation—An Effect That Is Inhibited by the Hypoxia-Activated Prodrug TH-302
Jasdeep K. Saggar and Ian F. Tannock

2115 Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors

2127 Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer
Table of Contents

2167  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma

2177  Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Lorenz Jahn, Margot J. Pont, Arnoud H. de Ru, Cornelis A.M. van Bergen, Marieke Griffioen, J.H. Frederik Falkenburg, Peter A. van Veelen, and Mirjam H.M. Heemskerk

LETTERS TO THE EDITOR

2187  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Letter
Steven Sorscher

2188  RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer—Response
Rona Yaeger and Leonard B. Saltz

RETRACTION

2189  Retraction: Glioma-Associated Cancer-Initiating Cells Induce Immunosuppression

CORRECTIONS

2190  Correction: Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer

2192  Correction: Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

ABOUT THE COVER

The cover shows establishment of blood brain barrier (BBB) tight junctions. Immunofluorescence staining demonstrates ZO-1 expression within the top endothelial layer of an in vitro BBB. For details, see the article by Jilaveanu and colleagues on page 2138 of this issue.